Unlike the previous purely conceptual hype, this wave of increase appears to be well-founded. As annual reports are gradually released, leading CXOs have seen their revenue double, gross margins significantly improve, and orders surge. Although the next day, the sector failed to maintain its strong momentum. However, the growth in performance has led to expectations of an industry recovery.

Wecare Probiotics Co., Ltd., ranked #1 in China and #3 globally by probiotic powder production volume, has filed for a Hong Kong IPO. The company reported 2025 revenue of RMB 701.5 million (+28.9% YoY), driven by strong demand for human health probiotic powders and rapid expansion in North America, where revenue surged 70.1%. Despite a dip in net profit to RMB 65.2 million (−18.1% YoY) due to IPO-related expenses and R&D investments, adjusted net profit rose 27.7% to RMB 106.9 million. With R&D intensity at 12.7% of revenue, a proprietary strain library of over 40,000 strains, and overseas revenue now accounting for 40.2% of total sales, Wecare is transitioning from a China-centric manufacturer to a global biotech innovator in the $3.26 billion global probiotics market.

Currently, the going global of Chinese medical devices is shifting from quantitative expansion to qualitative improvement. According to data from the China Chamber of Commerce for Import and Export of Medicines and Health Products, China's medical device export value reached USD 50.469 billion in 2025, representing a year-on-year increase of 3.54 percent. Against the industry backdrop of normalized volume-based procurement and intensifying domestic competition, an increasing number of medical device companies are turning their sights to overseas markets.

HH160 is a hexavalent trispecific antibody developed by Huahui Health based on its proprietary PolyBoost™ multispecific antibody platform. Constructed on a bevacizumab backbone, the molecular structure incorporates Fc-silencing modifications that eliminate antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), thereby reducing immune-related inflammatory responses.

Statistics from the National Healthcare Security Administration show that the intensity of healthcare security supervision continues to increase, with 34.2 billion yuan of healthcare security funds recovered and 10,357 criminal suspects arrested. Moreover, reforms in healthcare payment methods are deepening, and supervision is becoming increasingly stringent. However, due to factors such as a shortage of professional talent and limited system-building capabilities, hospitals face challenges in achieving refined healthcare security management. In response, Singularity Smart Security (Beijing) Technology Co., Ltd. has emerged, with its self-developed "Healthcare Intelligence Hub" platform already implemented in nearly 100 hospitals across 15 provinces in China. The platform's success lies in its precise understanding of the pain points hospitals encounter in refined healthcare security management and its construction of effective solutions. Currently, most hospitals face four major challenges in refined healthcare security management, including obstacles to precise cost control caused by叠加的信息差与思维错位. Although the DRG/DIP payment mechanism aims to force hospitals to control costs and improve efficiency, in practice, hospitals still need to overcome significant difficulties.

Centered on the core mission of de novo functional antibody design, Aureka Biotechnologies is building a customized high-throughput and high-content experimental infrastructure to support its generative antibody design system, enhancing the evolutionary efficiency of model and process iteration, and scaling up the production of differentiated, high-value innovative functional antibodies.

Xinbai Pharmaceutical is a biochemical pharmaceutical enterprise with a deep historical foundation and a rare high-quality niche asset within the China Resources pharmaceutical system. The company, with a registered capital of 148 million RMB, is registered in the Nanjing Economic and Technological Development Zone and boasts four major production workshops: small-volume injections, lyophilized powder injections, biochemical extraction, and oral solid preparations. Its overall asset operation remains stable.

Preliminary statistics from VCBeat tracked 13 financing events in China's healthcare sector between April 20 and 24, 2026 (excluding IPOs and private placements). The period was led by Pulnovo Medical's USD 100 million Series D round, followed by SenseTime's RMB 500 million.

Beijing QL Biopharmaceutical Co., Ltd. has submitted its draft prospectus for a Hong Kong Stock Exchange listing. The company, founded in 2018, focuses on metabolic diseases including obesity, type 2 diabetes, MASH, and severe hypertriglyceridemia. Its core product, ZT002, is a once-monthly GLP-1 receptor agonist currently in Phase III trials in China, with potential to become the world’s first approved monthly GLP-1 RA. QL Biopharm reported RMB 3.1 million in non-commercial revenue and a net loss of RMB 191.4 million in 2025, with RMB 176.1 million spent on R&D. The company holds eight pipeline candidates across clinical and preclinical stages, supported by proprietary platforms such as QL Long and QL Oral, and operates a GMP manufacturing facility in Taizhou.

VCBeat's latest monthly report breaks down the top financings, most active investors, and key licensing deals, offering a data-driven snapshot of where the market is heading next. Gain the clarity needed to track shifting capital flows and emerging partnership trends.